Furthermore, administration of mGluR5 antagonists in FMR1 knockout mice demonstrated a variety of benefits in this preclinical FXS model phenotype, including reduced seizures and anxiety-like behaviors [64]. Here, GRM5 is linked to fragile X syndrome.